A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis

BACKGROUND: Fibroblast growth factor 21 (FGF21) has become a promising therapeutic target for metabolic diseases such as type 2 diabetes (T2D), obesity and non-alcoholic steatohepatitis. However, the clinical application of natural FGF21 molecule is limited because of its instability in vitro and sh...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Qi, Lin, Shushan, Li, Yu, Liu, Liang, Li, Xiaoping, Gao, Xianglei, Yan, Jiangyu, Gu, Baohua, Chen, Xiaofeng, Li, Wenjia, Tang, Xinfa, Chen, Chao, Guo, Lixin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7806870/
https://www.ncbi.nlm.nih.gov/pubmed/33421947
http://dx.doi.org/10.1016/j.ebiom.2020.103202

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7806870/
https://www.ncbi.nlm.nih.gov/pubmed/33421947
http://dx.doi.org/10.1016/j.ebiom.2020.103202

Ejemplares similares